4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 101 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q2 2023. The put-call ratio across all filers is 1.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,290,807 | -31.6% | 258,508 | -2.8% | 0.00% | 0.0% |
| Q2 2023 | $4,808,011 | +28.2% | 266,077 | +22.0% | 0.00% | 0.0% |
| Q1 2023 | $3,749,242 | -22.2% | 218,106 | +0.6% | 0.00% | -50.0% |
| Q4 2022 | $4,817,349 | +184.0% | 216,900 | +2.8% | 0.00% | +100.0% |
| Q3 2022 | $1,696,000 | +37.9% | 210,942 | +19.8% | 0.00% | – |
| Q2 2022 | $1,230,000 | -57.1% | 176,101 | -7.1% | 0.00% | -100.0% |
| Q1 2022 | $2,867,000 | -29.1% | 189,611 | +2.9% | 0.00% | 0.0% |
| Q4 2021 | $4,044,000 | +3.3% | 184,299 | +27.0% | 0.00% | 0.0% |
| Q3 2021 | $3,915,000 | +157.1% | 145,154 | +129.6% | 0.00% | 0.0% |
| Q2 2021 | $1,523,000 | -39.4% | 63,220 | +9.1% | 0.00% | 0.0% |
| Q1 2021 | $2,515,000 | – | 57,967 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |